In a bid to bolster its presence overseas, drug major Lupin is eyeing acquisitions in various global markets, including the US, Latin America and Europe. The company, which has already entered the Mexican market, would also continue to look for acquisitions in key Latam markets such as Brazil.
During the last fiscal, global markets (excluding India) accounted for around 75 per cent of the company’s total revenues, which stood over Rs 11,000 crore.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |